Advances in understanding the molecular mechanisms of necrobiosis and therefore the pathologic process of intermittent and familial Parkinson's disease are making new opportunities for the development of Neuroprotectiveand/or neurorestorative therapies. Current therapies for Parkinson’s disease ameliorate symptoms within the early phases of disease however become less effective over time, as the underlying disease progresses. Therapies that slow the progression of Parkinson’s disease are required. However, there are comparatively few clinical trials aimed toward demonstrating neuroprotection. Many potential Neuroprotective compounds, representing a wide range of mechanisms, are out there and benefit further investigation in Parkinson’s disease.